dr. tal zaks on the jak2 inhibitor sar302503 in myelofibrosis
Published 11 years ago • 971 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:23
dr. tal zaks on treatments and pathways in myelofibrosis
-
1:21
dr. zaks describes the mechanism of action of sar302503
-
1:15
dr. tal zaks on patient-reported symptom assessments
-
2:22
dr. mesa on the evolving role of jak2 inhibitors in myelofibrosis
-
1:19
dr. srdan verstovsek on jak2 inhibitors as a treatment for myelofibrosis
-
2:06
second-line myelofibrosis treatment – the potential of jak2 inhibitor ns-018
-
22:45
myelofibrosis and jak mutations (podcast)
-
14:05
myelofibrosis: emerging jak2 inhibitor combination treatment strategies
-
44:17
sglt-2 i, natriuresis & aquaresis: dapa shuttle-1 - dr. a. marton and prof. dr. j. titze (singapore)
-
18:04
how mrna medicine will change the world | melissa j. moore | ted
-
51:48
world leading geneticist and immunologist josef penninger on potential covid-19 treatment
-
10:15
rewriting the genetic code: a cancer cure in the making | tal zaks | tedxbeaconstreet
-
1:33
dr. mesa on late-stage trials in myelofibrosis
-
0:45
moderna chief reflects on vaccine development
-
0:49
axios on hbo: moderna chief medical officer tal zaks (promo) | hbo
-
2:19
human mcts1-dependent translation of jak2 is essential for ifn-γ immunity to mycobacteria
-
1:56
dr. cervantes discusses comfort-ii long-term data
-
1:30
dr. sartor on the vision trial in mcrpc
-
20:42
beyond jak2 inhibitors: new targets and new agents
-
4:54
what are the primary ingredients in the moderna and pfizer vaccines? - dr. t
-
2:57
ntu hospital study finds mixing az with moderna more effective than 2 az doses
-
1:40
justin balko on jak2 amplification in triple-negative breast cancer